| 包装 | 价格(元) |
| 10mM (in 1mL Water) | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 100mg | 电议 |
Cell lines | Human lung carcinoma (A549) cell lines |
Preparation Method | About 1×105A549 cells/well were plated into 12-well culture dishes and incubated for 24h. After 24h, doxorubicin, as well as conjugates of doxorubicin at a concentration equivalent to 2μg/ml of doxorubicin was added and incubated for time periods of 4 and 12h. |
Reaction Conditions | 2μg/ml |
Applications | The uptake of the free doxorubicin and conjugates into the A549 cells increased with time. The fluorescent images of cells treated with free doxorubicin and polymannose(PM)-doxorubicin showed better uptake, while the sodium alginate(SA)-doxorubicin showed significantly lesser uptake after 4 and 12h exposure. |
Animal models | BALB/c mice (5-6 weeks, female) and BALB/c athymic nude mice (nu/nu, 5-6 weeks, male) |
Preparation Method | For in vivo tumor implantation, C26 cells at 5×105cells in 30μL Minimum Essential Medium (MEM) and MIA PaCa-2 cells at 2×106cells in 50μL 10:90 v/v MEM: Matrigel matrix were inoculated in the right flank of normal and athymic nude BALB/c mice, respectively. Tumor cells were allowed to grow until the tumor volume-reached 75-100mm3for C26 tumors and 100-125mm3 for MIA PaCa-2 tumors. Tumor-bearing mice were then treated with a single i.v. injection of albumin-binding domain-doxorubicin (ABD-DoX) at 10 and 20mg doxorubicin equiv. kg-1BW, AlDoxorubicin at 20mg doxorubicin equiv. kg-1BW, and free doxorubicin at 10mg·kg-1BW. |
Dosage form | ABD-Doxorubicin at 10 and 20mg doxorubicin equiv. kg-1 BW, AlDoxorubicin at 20mg doxorubicin equiv. kg-1BW, and free doxorubicin at 10mg kg-1BW. |
Applications | ABD-Doxorubicin has superior therapeutic efficacy to AlDoxorubicin in the syngeneic C26 colon carcinoma model in BALB/c mice and in the MIA PaCa-2 pancreatic adenocarcinoma xenograft model in nude mice, and that both formulations are superior to free Doxorubicin. |
| 文献引用 | |
| 产品描述 | Doxorubicin(DOX), also known as adriamycin, is a compound of the anthracycline class that has the broadest spectrum of activity[1]. Doxorubicin inhibits topoisomerase Ⅱ and topoisomerase Ⅰ with IC50of 2.67μM and 0.8μM, respectively[2,3]. It is widely used for the treatment of various solid tumors via interacting with deoxyribonucleic acid, but it is limited in the clinical application due to severe side effect[4] Doxorubicin can be loaded into liposomes by transmembrane pH gradient method to get high encapsulation efficiency with high drug/lipid ratio. Liposomal doxorubicin is a successful clinical formulation, and also a perfect model drug system for cancer-therapy research[5]. A considerable amount of doxorubicin can accumulate in human placental tissue. Both doxorubicin and its pH-sensitive liposomal formulation, L-Doxorubicin, are efficiently internalized by human trophoblastic BeWo cells and that doxorubicin accumulates in placental tissue so that decrease the exposure of fetal[6] Doxorubicin combines with cobimetinib at sublethal dose completely arrested osteosarcoma growth. Targeted MEK inhibition by cobimetinib enhances doxorubicin’s efficacy in osteosarcoma models[7]. Doxorubicin is frequently used as an adjuvant chemotherapeutic agent for breast cancer. Silk films loaded with doxorubicin provide locoregional control of human breast cancer in vivo. By manipulating silk crystallinity or β-sheet content, the doxorubicin release rate could be controlled. Both soluble and stabilised silk films loaded with doxorubicin had a significantly greater primary tumour response than the equivalent dose of doxorubicin administered intravenously in the absence of the silk film carrier. The future use of this approach for localised chemotherapy is promising[8] References: |
m.cnreagent.com